Relatlimab clinical trials
Also written BMS-986016.
Counted the way a researcher would: Relatlimab with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses relatlimab has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the relatlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Mar 2022 · OPDUALAG · BLA 761234 (FDA, Drugs@FDA; in a combination)
- European Union
- 15 Sept 2022 · Opdualag · EMEA/H/C/005481 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Studies by the year they started
50 studies that test it; most in 2019 (8)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 8 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 6 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 19 · Other 31
Bristol-Myers Squibb (19) · National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · Dan Zandberg (1) · Melanoma Institute Australia (1) · The Netherlands Cancer Institute (1)
Often tested with
Tested in the same studies.
Nivolumab (25) · Ipilimumab (11) · Linrodostat (3) · Dasatinib (2) · Sunitinib (2) · Nivolumab, relatlimab drug combination (2) · Rucaparib (2) · Adavosertib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 4 phase 3 studies under way
Relatlimab is the comparator. A study of two new drugs counts under both.
- 1Fianlimab · Regeneron Pharmaceuticals · next primary completion Mar 2027
- 1Cemiplimab · Regeneron Pharmaceuticals · next primary completion Mar 2027
- 1Anzutresgene autoleucel · Immatics US, Inc. · next primary completion Jan 2028
- 1Vusolimogene oderparepvec · Replimune, Inc. · next primary completion Sep 2030
- 1Brenetafusp · Immunocore Ltd · next primary completion Oct 2027
Reaching primary completion within a year · 6
Studies that test relatlimab.
- Nov 2026Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesPhase 2 · Stanford University
- Dec 2026Nivolumab for Treatment of Squamous Cell Carcinoma of the SkinPhase 2 · Salzburger Landeskliniken
- Dec 2026ARID1A and/or KDM6A Mutation and CXCL13 ExpressionPhase 2 · M.D. Anderson Cancer Center
- Jul 2027Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaPhase 2 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Jul 2027Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal MedullaPhase 2 · M.D. Anderson Cancer Center
- Oct 2027Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorPhase 2 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Studies
Open first, then newest update. How each study uses relatlimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 50
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyRecruitingPhase 2/3National Cancer Institute (NCI)NCT05987241Written as RelatlimabReport a problem
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingPhase 3Bristol-Myers SquibbNCT06561386Written as RelatlimabReport a problem
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as RelatlimabReport a problem
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06029270Written as RelatlimabReport a problem
- Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06683755Written as RelatlimabReport a problem
- ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabRecruitingPhase 2NYU Langone HealthNCT07504796Written as RelatlimabReport a problem
- A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaNot yet recruitingPhase 4Bristol-Myers SquibbNCT07459543Written as Nivolumab + RelatlimabReport a problem
- Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell CarcinomaRecruitingPhase 2University of California, San DiegoNCT06624475Written as Relatlimab plus NivolumabReport a problem
- Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05704647Written as RelatlimabReport a problem
- Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesRecruitingPhase 2Stanford UniversityNCT06712927Written as Nivolumab + Relatlimab FDCReport a problem
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03521830Written as RelatlimabReport a problem
- Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06295159Written as Nivolumab + RelatlimabReport a problem
- Nivolumab for Treatment of Squamous Cell Carcinoma of the SkinRecruitingPhase 2Salzburger LandesklinikenNCT04204837Written as Nivolumab plus RelatlimabReport a problem
- Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AMLRecruitingPhase 2Ludwig-Maximilians - University of MunichNCT04913922Written as RelatlimabReport a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as RelatlimabReport a problem
- Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaSuspendedPhase 2National Cancer Institute (NCI)NCT06325683Written as RelatlimabReport a problem
- A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver CancerCompletedPhase 1/2Bristol-Myers SquibbNCT05337137Written as RelatlimabReport a problem
- Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03607890Written as RelatlimabReport a problem
- Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal MedullaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05347212Written as RelatlimabReport a problem
- ARID1A and/or KDM6A Mutation and CXCL13 ExpressionActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04953104Written as RelatlimabReport a problem
See all 50 studies that test relatlimab →
Tested with established drugs · 15 — they are given beside it
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyRecruitingPhase 2/3National Cancer Institute (NCI)NCT05987241Written as RelatlimabReport a problem
- Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AMLRecruitingPhase 2Ludwig-Maximilians - University of MunichNCT04913922Written as RelatlimabReport a problem
- A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver CancerCompletedPhase 1/2Bristol-Myers SquibbNCT05337137Written as RelatlimabReport a problem
- Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03607890Written as RelatlimabReport a problem
- ARID1A and/or KDM6A Mutation and CXCL13 ExpressionActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04953104Written as RelatlimabReport a problem
- A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2Bristol-Myers SquibbNCT04623775Written as RelatlimabReport a problem
- Nivolumab Plus Relatlimab in Patients With Metastatic Uveal MelanomaCompletedPhase 2Jose Lutzky, MDNCT04552223Written as RelatlimabReport a problem
- A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaTerminatedPhase 3Bristol-Myers SquibbNCT05002569Written as Nivolumab + Relatlimab Fixed Dose CombinationReport a problem
- Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal CancerCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03642067Written as RelatlimabReport a problem
- Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT02966548Written as RelatlimabReport a problem
- Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeCompletedPhase 1National Institute of Neurological Disorders and Stroke (NINDS)NCT03493932Written as BMS-986016Report a problem
- A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) TreatmentTerminatedPhase 1Bristol-Myers SquibbNCT03978611Written as RelatlimabReport a problem
- Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)WithdrawnPhase 2National Cancer Institute (NCI)NCT06400264Written as RelatlimabReport a problem
- Nivolumab and Relatlimab in Treating Participants With Advanced ChordomaCompletedPhase 2Jonsson Comprehensive Cancer CenterNCT03623854Written as RelatlimabReport a problem
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell MalignanciesCompletedPhase 1/2Bristol-Myers SquibbNCT02061761Written as BMS-986016Report a problem
Tested in a combination · 35 — another drug in the study is under test too
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingPhase 3Bristol-Myers SquibbNCT06561386Written as RelatlimabReport a problem
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as RelatlimabReport a problem
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06029270Written as RelatlimabReport a problem
- Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06683755Written as RelatlimabReport a problem
- ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabRecruitingPhase 2NYU Langone HealthNCT07504796Written as RelatlimabReport a problem
- A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaNot yet recruitingPhase 4Bristol-Myers SquibbNCT07459543Written as Nivolumab + RelatlimabReport a problem
- Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell CarcinomaRecruitingPhase 2University of California, San DiegoNCT06624475Written as Relatlimab plus NivolumabReport a problem
- Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05704647Written as RelatlimabReport a problem
- Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesRecruitingPhase 2Stanford UniversityNCT06712927Written as Nivolumab + Relatlimab FDCReport a problem
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03521830Written as RelatlimabReport a problem
- Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06295159Written as Nivolumab + RelatlimabReport a problem
- Nivolumab for Treatment of Squamous Cell Carcinoma of the SkinRecruitingPhase 2Salzburger LandesklinikenNCT04204837Written as Nivolumab plus RelatlimabReport a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as RelatlimabReport a problem
- Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaSuspendedPhase 2National Cancer Institute (NCI)NCT06325683Written as RelatlimabReport a problem
- Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal MedullaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05347212Written as RelatlimabReport a problem
- A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsActive, not recruitingPhase 2Bristol-Myers SquibbNCT06101134Written as relatlimab+nivolumabReport a problem
- Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck CancerActive, not recruitingPhase 2Dan ZandbergNCT04080804Written as RelatlimabReport a problem
- Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic SettingCompletedPhase 2John KirkwoodNCT03743766Written as RelatlimabReport a problem
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaActive, not recruitingPhase 3Bristol-Myers SquibbNCT05625399Written as Nivolumab + RelatlimabReport a problem
- Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.WithdrawnPhase 2National Health Research Institutes, TaiwanNCT07369791Written as Nivolumab/RelatlimabReport a problem
Showing 20 of 35. See all 35 →
Given beside what is tested · 20 — usual care or a partner of the new treatment
- Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaRecruitingPhase 2NYU Langone HealthNCT05428007In every armWritten as Nivolumab/RelatlimabReport a problem
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsRecruitingPhase 1ExelixisNCT05176483Written as Nivolumab + RelatlimabReport a problem
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerRecruitingPhase 2The Netherlands Cancer InstituteNCT03026140Written as Relatlimab (BMS-986016)Report a problem
- Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and RelatlimabRecruitingPhase 2Duke UniversityNCT06816927Written as RelatlimabReport a problem
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaRecruitingPhase 1Carlo ContrerasNCT04697576Written as Nivolumab + RelatlimabReport a problem
- Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular CarcinomaActive, not recruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04658147Written as RelatlimabReport a problem
- PD-1 Antibody Therapy + Infliximab for Metastatic MelanomaActive, not recruitingPhase 2Massachusetts General HospitalNCT05034536In every armWritten as RelatlimabReport a problem
- Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without RelatlimabActive, not recruitingPhase 2The Netherlands Cancer InstituteNCT06237920Written as RelatlimabReport a problem
- Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer PatientsCompletedPhase 2University Hospital, EssenNCT04205552Written as Relatlimab 10 MG/ML Intravenous SolutionReport a problem
- REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric CancerActive, not recruitingPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03610711Written as RelatlimabReport a problem
- An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedPhase 1/2Bristol-Myers SquibbNCT03459222In every armWritten as RelatlimabReport a problem
- Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal CancerActive, not recruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03044613Written as RelatlimabReport a problem
- Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior ImmunotherapyCompletedPhase 2Dan ZandbergNCT04326257Written as Nivolumab+RelatlimabReport a problem
- A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase InhibitorsCompletedPhase 2Bristol-Myers SquibbNCT04567615Written as RelatlimabReport a problem
- A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadCompletedPhase 2Bristol-Myers SquibbNCT02060188Written as BMS-986016Report a problem
- A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaActive, not recruitingPhase 2/3Bristol-Myers SquibbNCT03470922Written as RelatlimabReport a problem
- T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerTerminatedPhase 1/2Inge Marie SvaneNCT04611126In every armWritten as RelatlimabReport a problem
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesCompletedPhase 1/2CelgeneNCT03310619Written as RelatlimabReport a problem
- An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated TumorsCompletedPhase 1/2Bristol-Myers SquibbNCT02488759Written as RelatlimabReport a problem
- A Phase 1, Bioavailability Study of Relatlimab in Combination With NivolumabCompletedPhase 1Bristol-Myers SquibbNCT04112498In every armWritten as relatlimabReport a problem
As the comparator · 4 — what is tested is compared with relatlimab
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)RecruitingPhase 3Regeneron PharmaceuticalsNCT06246916Written as relatlimab+nivolumabReport a problem
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingPhase 3Immatics US, Inc.NCT06743126Written as nivolumab plus relatlimabReport a problem
- VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]RecruitingPhase 3Replimune, Inc.NCT06264180Written as Nivolumab + RelatlimabReport a problem
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)RecruitingPhase 3Immunocore LtdNCT06112314Written as Nivolumab + RelatlimabReport a problem
Observed · 5 — patients on it are followed, or it is given outside a trial
- Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic MelanomaRecruitingJohn KirkwoodNCT07223411Written as Relatlimab + NivolumabReport a problem
- Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+IpilimumabCompletedBristol-Myers SquibbNCT07091695Written as Nivolumab + relatlimabReport a problem
- Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron DatabaseCompletedBristol-Myers SquibbNCT07079644Written as Nivolumab + RelatlimabReport a problem
- Expanded Access for RelatlimabNo longer availableBristol-Myers SquibbNCT05170659Written as RelatlimabReport a problem
- Expanded Access for Fixed-Dose Combination of Nivolumab Plus RelatlimabNo longer availableBristol-Myers SquibbNCT05170685Written as Nivolumab plus Relatlimab FDCReport a problem
Codes
What other systems call relatlimab · ClinicalTrials.gg INT001801
- MeSH (NLM) C000721227relatlimabOne source ClinicalTrials.gov
- UNII (FDA) AF75XOF6W3RELATLIMABConfirmed FDA, Wikidata
- RxNorm 2596773One source FDA
- Wikidata Q58315670relatlimabConfirmed FDA, Wikidata
- NCI Thesaurus C111999RelatlimabOne source FDA
- DrugBank DB14851One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000721227 | relatlimab | One source ClinicalTrials.gov |
| UNII (FDA) | AF75XOF6W3 | RELATLIMAB | Confirmed FDA, Wikidata |
| RxNorm | 2596773 | — | One source FDA |
| Wikidata | Q58315670 | relatlimab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C111999 | Relatlimab | One source FDA |
| DrugBank | DB14851 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.